HUTCHMED (China) Limited HCM
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -1.35%
- 1 year
- -8.87%
- Open
- 13.26
- Prev close
- 13.59
- Mkt cap
- 2.29B
- Vol
- 33.49K
- Avg vol
- 66.77K
- EPS
- 0.10
- P/E
- 131.50
- Div yield
- 0.00%
More statistics
- Low
- 13.14
- High
- 13.42
- Forward P/E
- 50.73
- Beta
- 0.36
- Short ratio
- 4.66
- Inst. own
- 2.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 4, 2027
- 50-d avg
- 13.64
- 200-d avg
- 13.23
- 1y target
- 20.59
News
10 hours ago globenewswire.com
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
2 days ago globenewswire.com
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
-
4 days ago benzinga.com
Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
4 days ago globenewswire.com
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this…
6 days ago gurufocus.com
Firms in Asia Pacific Embrace Unified Workday Platforms
Organizations across Asia Pacific are replacing fragmented legacy finance and human capital management (HCM) environments with a connected Workday platform that
6 days ago globenewswire.com
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with…
6 days ago gurufocus.com
AI Brings U.S. Enterprises More Value from Workday
Enterprises in the U.S. are asking Workday service providers to support AI adoption, platform expansion and continuous optimization to make finance and human ca
-
1 week ago benzinga.com
HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…
1 week ago globenewswire.com
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
-
1 week ago benzinga.com
HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…